Cilostazol treatment of claudication in diabetic patients

被引:13
作者
Rendell, M
Cariski, AT
Hittel, N
Zhang, P
机构
[1] Creighton Diabetes Ctr, Omaha, NE 68106 USA
[2] Otsuka Amer Pharmaceut Inc, Rockville, MD USA
[3] Otsuka Pharma GMBH, Frankfurt, Germany
关键词
peripheral arterial disease; intermittent claudication; diabetes; cilostazol; absolute claudication distance;
D O I
10.1185/030079902125001245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare the efficacy and safety of cilostazol in diabetic and non-diabetic patients from eight (six placebo- and two active-controlled) randomised, double-blind phase III trials. Design: We only included patients from the trial data set receiving cilostazol 100 mg twice daily (216 diabetic/599 non-diabetic) or placebo (220/616). Efficacy was measured by absolute claudication distance (ACD), using standard treadmill exercise protocols. Results: Among diabetic and non-diabetic patients, cilostazol was superior to placebo (estimated treatment effect 1.15, 95% confidence interval, 1.05-1.25, p = 0.001; and 1.24,1.18-1.31, p < 0.0001, respectively). There was no statistical difference in response between diabetic and non-diabetic subjects. In the efficacy analysis, cilostazol-treated diabetic subjects with the lowest baseline ACD (but not those with greater baseline ACD) walked approximately 34% farther than at baseline, whereas their non-diabetic counterparts walked 23% farther. There was no significant difference in the adverse event profile of the diabetic and non-diabetic patients on cilostazol. No excess haemorrhagic events occurred in cilostazol-treated diabetic patients. Trial duration varied from 12 to 24 weeks. Conclusions: Diabetic and non-diabetic patients with intermittent claudication respond favourably to cilostazol, with no significant difference in their overall response. Diabetic individuals with the most severe claudication respond better than those less affected, but the response of non-diabetic patients increases as baseline ACD increases. Adverse event incidence was comparable in the two populations, although diabetic patients might be expected to experience greater morbidity. Cilostazol is a safe and effective treatment for claudication in diabetic and non-diabetic populations.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 50 条
  • [31] Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6
    Lee, TM
    Su, SF
    Hwang, JJ
    Tseng, CD
    Chen, MF
    Lee, YT
    Wang, SS
    ATHEROSCLEROSIS, 2001, 158 (02) : 471 - 476
  • [32] Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients
    Farkas Katalin
    Kolossvary Endre
    Jarai Zoltan
    ORVOSI HETILAP, 2020, 161 (38) : 1637 - 1645
  • [33] Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease
    de Franciscis, Stefano
    Gallelli, Luca
    Battaglia, Luigi
    Molinari, Vincenzo
    Montemurro, Rossella
    Stillitano, Domenico M.
    Buffone, Gianluca
    Serra, Raffaele
    INTERNATIONAL WOUND JOURNAL, 2015, 12 (03) : 250 - 253
  • [35] Cost-effectiveness analysis of cilostazol vs naftidrofuryl and pentoxifylline for the treatment of intermittent claudication in Spain
    Brosa, M.
    Garcia-Cases, C.
    Clerch, L.
    March, J. R.
    Lozano, F. S.
    ANGIOLOGIA, 2011, 63 (03): : 103 - 107
  • [36] Pharmacological treatment in the patient with intermittent claudication
    Rodriguez-Morata, A.
    Esteban-Gracia, C.
    Fernandez-Heredero, A.
    Riera-Vazquez, R.
    Vaquero-Lorenzo, F.
    March-Garcia, J. R.
    ANGIOLOGIA, 2011, 63 (03): : 113 - 118
  • [37] Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 16301638)
    Roset, P. N.
    BRITISH JOURNAL OF SURGERY, 2013, 100 (13) : 1838 - 1838
  • [38] Reliability of the Vascular Claudication Reporting in Diabetic Patients With Peripheral Arterial Disease: A Study With Near-Infrared Spectroscopy
    Manfredini, Fabio
    Lamberti, Nicola
    Malagoni, Anna Maria
    Zambon, Christel
    Basaglia, Nino
    Mascoli, Francesco
    Manfredini, Roberto
    Zamboni, Paolo
    ANGIOLOGY, 2015, 66 (04) : 365 - 374
  • [39] Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication
    Mohler, ER
    Beebe, HG
    Salles-Cuhna, S
    Zimet, R
    Zhang, P
    Heckman, J
    Forbes, WP
    VASCULAR MEDICINE, 2001, 6 (03) : 151 - 156
  • [40] Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients
    Mitsuhashi, N
    Tanaka, Y
    Kubo, S
    Ogawa, S
    Hayashi, C
    Uchino, H
    Shimizu, T
    Watada, H
    Kawasumi, M
    Onuma, T
    Kawamori, R
    ENDOCRINE JOURNAL, 2004, 51 (06) : 545 - 550